Juvenile Myelomonocytic Leukemia malady

Wikipedia: Juvenile myelomonocytic leukemia (JMML) is a serious chronic leukemia (cancer of the blood) that affects...⁴⁴ more...

MalaCards: Juvenile Myelomonocytic Leukemia, also known as leukemia, juvenile myelomonocytic, is related to acute lymphoblastic leukemia and acute promyelocytic leukemia. An important gene associated with Juvenile Myelomonocytic Leukemia is NRAS (neuroblastoma RAS viral (v-ras) oncogene homolog), and among its related pathways are ErbB2-ErbB3 Heterodimers and Development_EGFR signaling via small GTPases. The drugs isotretinoin and methotrexate and the compounds threonine and inositol have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and t cells, and related mouse phenotypes are endocrine/exocrine gland and respiratory system.

OMIM: 607785

Aliases & Descriptions:

juvenile myelomonocytic leukemia 6 30 8 32 43 leukemia, juvenile myelomonocytic 30 33

leukemia 43 jmml 30

Diseases related to juvenile myelomonocytic leukemia by text searches and GeneDecks gene sharing:

(show top 50)    (show all 616)

id	Related Disease	Score	Top Affiliating Genes
1	acute lymphoblastic leukemia	38.6	KIR3DL1, JAK2, FLT3, INPP5D, HRAS, PTPN11
2	acute promyelocytic leukemia	36.9	RARA, IRF1, FLT3, ANXA2, PTPN3, NRAS
3	t-cell leukemia	35.0	BRAF, JAK2, CDKN3, IRF1, FLT3, INPP5D
4	acute leukemia	34.6	RARA, JAK2, IRF1, FLT3, INPP5D, CBL
5	monocytic leukemia	34.5	RARA, FLT3, TP53, CSF2, RUNX1
6	human t-cell leukemia virus type 1	34.5	JAK2, CDKN3, IL13, TP53, STAT5A
7	lymphoblastic leukemia	34.4	KIR3DL1, BRAF, RARA, RASA1, JAK2, CDKN3
8	megakaryoblastic leukemia	33.9	JAK2, FLT3, STAT5A, CSF2, RUNX1
9	childhood leukemia	33.8	CDKN3, TP53, TET2, PTPN11, CSF2, RUNX1
10	acute monocytic leukemia	33.5	RARA, FLT3, TP53, CSF2
11	down syndrome	33.3	RARA, JAK2, FLT3, RUNX1
12	chronic lymphocytic leukemia	33.3	KIR3DL1, BRAF, RAF1, MX1, JAK2, IL13
13	acute megakaryoblastic leukemia	33.0	JAK2, FLT3, RUNX1
14	chronic myeloid leukemia	32.8	KIR3DL1, RARA, RAF1, RASA1, JAK2, IRF2
15	megakaryocytic leukemia	32.5	JAK2, TP53, CSF2, RUNX1
16	plasma cell leukemia	31.8	BRAF, NRAS, KRAS
17	acute lymphoblastic leukemia, childhood	31.7	FLT3, PTPN11, KRAS, RUNX1
18	neutropenia	31.5	JAK2, INPP5D, PTPN3, PTPN11, STAT5A, CSF2
19	lymphoblastic lymphoma	30.9	TP53, PDGFRB, KRAS, RUNX1
20	graft versus host disease	30.7	KIR3DL1, IRF1, IL13, PDGFRA, PDGFRB, CSF2
21	hematopoiesis	30.5	JAK2, FLT3, INPP5D, TET2, PTPN11, SPRED1
22	myelofibrosis	30.5	JAK2, FLT3, STAT5A
23	acute myeloid leukemia, adult	30.5	JAK2, KRAS
24	neurofibromatosis	30.2	RASA2, RAF1, RASA1, HRAS, PTPN11, NF1
25	chronic myelomonocytic leukemia	29.5	JAK2, FLT3, TET2, PTPN11, NRAS, NF1
26	hypereosinophilic syndrome	29.5	JAK2, IL13, PDGFRA, PDGFRB, CSF2
27	severe congenital neutropenia	29.4	JAK2, INPP5D, PTPN3, PTPN11, STAT5A, CSF2
28	anemia	29.3	MX1, JAK2, IRF1, FLT3, IL13, CBL
29	eosinophilia	29.1	JAK2, IL13, PDGFRA, PDGFRB, CSF2
30	immunodeficiency	29.0	KIR3DL1, CDKN3, IL13, CBL, CBLB, PTPN3
31	non-hodgkin lymphoma	28.8	KIR3DL1, BRAF, RAF1, RASA1, CDKN3, FLT3
32	b-cell lymphomas	28.7	KIR3DL1, JAK2, CDKN3, IRF1, INPP5D, IL13
33	noonan syndrome	28.6	BRAF, RAF1, JAK2, IL13, HRAS, TP53
34	mastocytosis	28.4	RARA, JAK2, IL13, CBL, TET2, NRAS
35	myeloproliferative disorder	28.4	JAK2, FLT3, INPP5D, HRAS, PTPN11, NF1
36	retinoblastoma	28.2	RARA, RAF1, CDKN3, IRF1, HRAS, TP53
37	myelodysplastic syndrome	28.0	KIR3DL1, RARA, JAK2, IRF1, FLT3, ARHGAP26
38	thrombocytosis	28.0	JAK2, FLT3, TET2, NF1, PDGFRB, CSF2
39	li-fraumeni syndrome	27.9	RARA, TP53, PTEN, STAT5A
40	chronic myeloproliferative disease	27.8	JAK2, FLT3, PDGFRA, PDGFRB, STAT5A
41	hodgkin's lymphoma	27.5	KIR3DL1, BRAF, RAF1, RASA1, JAK2, CDKN3
42	myelomonocytic leukemia	27.4	KIR3DL1, BTD, NACA, BRAF, RASA2, RARA
43	was-related disorders	27.0	BRAF, RAF1, HRAS, PTPN11, SOS1
44	blindness	27.0	RARA, CDKN3, HRAS, TP53, PTEN, PDGFRA
45	mycosis fungoides	26.9	IL13, TP53, PTEN, PTPN11, STAT5A, GAB2
46	glioblastoma	26.8	CDKN3, IL13, ANXA2, TP53, PTEN, PDGFRA
47	myeloid malignancy	26.6	JAK2, FLT3, CBL, CBLB, TP53, TET2
48	histiocytosis	26.3	RARA, JAK2, FLT3, TP53, CSF2
49	glomerulonephritis	26.0	RARA, CDKN3, IL13, TP53, PDGFRB, CSF2
50	cutaneous t cell lymphoma	25.8	RARA, IL13, PTEN, PTPN11, STAT5A

Clinical features from OMIM: 607785

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 cytarabine, cytarabine liposome, doxorubicin hydrochloride, irinotecan, irinotecan hydrochloride, isotretinoin, methotrexate, methotrexate sodium, pipobroman, vincristine, vincristine sulfate

MalaCards organs/tissues related to juvenile myelomonocytic leukemia:

²²

MGI Mouse Phenotypes related to juvenile myelomonocytic leukemia:

²⁵ (show all 27)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland phenotype	MP:0005379	10.5	NF1, KRAS
2	respiratory system phenotype	MP:0005388	10.1	NF1, SPRED1, CBL, INPP5D
3	limbs/digits/tail phenotype	MP:0005371	9.4	KRAS, PDGFRA, NF1, NRAS, SPRED1, CBL
4	craniofacial phenotype	MP:0005382	9.2	CSF2, SOS1, PDGFRB, PDGFRA, NF1, SPRED1
5	liver/biliary system phenotype	MP:0005370	9.1	RUNX1, STAT5A, NF1, TET2, TP53, CBLB
6	other phenotype	MP:0005395	9.0	CSF2, PDGFRA, NF1, IL13, IRF2, JAK2
7	reproductive system phenotype	MP:0005389	8.7	CSF2, STAT5A, KRAS, PDGFRA, PTPN11, HRAS
8	digestive/alimentary phenotype	MP:0005381	8.4	SOS1, KRAS, PDGFRB, PDGFRA, NRAS, PTEN
9	pigmentation phenotype	MP:0001186	8.3	KRAS, PDGFRA, NF1, PTPN11, PTEN, TP53
10	hematopoietic system phenotype	MP:0005397	7.9	RUNX1, SIPA1, GAB2, CSF2, KRAS, PDGFRA
11	adipose tissue phenotype	MP:0005375	7.9	CSF2, STAT5A, PDGFRB, PTPN11, PTEN, TP53
12	vision/eye phenotype	MP:0005391	7.4	NRAS, NF1, PDGFRB, KRAS, SOS1, PTPN11
13	renal/urinary system phenotype	MP:0005367	7.3	NF1, PDGFRA, PDGFRB, KRAS, CSF2, PTEN
14	no phenotypic analysis	MP:0003012	7.1	RUNX1, SOS1, PTPN11, PTPN3, TET2, TP53
15	immune system phenotype	MP:0005387	7.0	PTPN11, SPRED1, NRAS, NF1, PDGFRA, PDGFRB
16	muscle phenotype	MP:0005369	6.8	PTPN11, NF1, PDGFRA, PDGFRB, KRAS, SOS1
17	nervous system phenotype	MP:0003631	6.6	SPRED1, NF1, PDGFRA, PDGFRB, KRAS, SOS1
18	embryogenesis phenotype	MP:0005380	6.5	NF1, PDGFRA, PDGFRB, KRAS, SOS1, CSF2
19	tumorigenesis	MP:0002006	6.5	TP53, TET2, PTEN, PTPN11, NRAS, NF1
20	skeleton phenotype	MP:0005390	5.7	TP53, PTEN, PTPN3, PTPN11, CSF2, RUNX1
21	cardiovascular system phenotype	MP:0005385	5.3	PTPN11, NRAS, NF1, PDGFRA, PDGFRB, KRAS
22	normal phenotype	MP:0002873	5.1	PTPN11, NRAS, NF1, PDGFRA, PDGFRB, KRAS
23	mortality/aging	MP:0010768	5.0	PTEN, PTPN11, NF1, PDGFRA, PDGFRB, STAT5A
24	integument phenotype	MP:0010771	4.8	JAK2, IRF1, IRF2, INPP5D, IL13, CBL
25	homeostasis/metabolism phenotype	MP:0005376	4.8	PTEN, PTPN11, NRAS, NF1, PDGFRA, PDGFRB
26	cellular phenotype	MP:0005384	4.2	PDGFRA, NF1, NRAS, PTPN11, PTEN, PDGFRB
27	growth/size phenotype	MP:0005378	3.2	BTD, TP53, TET2, PTEN, PTPN3, PTPN11

Articles related to juvenile myelomonocytic leukemia:

(show top 50)    (show all 53)

id	Title	Authors	Year	Affiliating Genes
1	Genetic analysis of TP53 in childhood myelodysplastic syndrome and juvenile myelomonocytic leukemia. (21784522)	Saito S.... Koike K.	2011	TP53
2	Germline PTPN11 mutation affecting exon 8 in a case o f syndromic juvenile myelomonocytic leukemia. (21106241)	Prontera P.... Donti E.	2011	PTPN11
3	Mutations of an E3 ubiquitin ligase c-Cbl but not TET 2 mutations are pathogenic in juvenile myelomonocytic leukemia. (20008299)	Muramatsu H.... Maciejewski J.P.	2010	PTPN11, CBL, NRAS
4	Germline CBL mutations cause developmental abnormalit ies and predispose to juvenile myelomonocytic leukemia. (20694012)	Niemeyer C.M.... Loh M.L.	2010	CBL
5	Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl. (20432758)	JakovljeviA8 G.... NakiA8 M.	2010	PTPN11
6	Does SPRED1 contribute to leukemogenesis in juvenile myelomonocytic leukemia (JMML)? (20339110)	Batz C.... Flotho C.	2010	SPRED1
7	Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia. (19798502)	Unal S.... Gurgey A.	2010	PTPN11
8	CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome. (20357823)	Shiba N.... Hayashi Y.	2010	CBL
9	PTEN deficiency is a common defect in juvenile myelomonocytic leukemia. (19010541)	Liu Y.L.... Emanuel P.D.	2009	PTEN
10	Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation. (18784923)	Raepple D.... Scheele J.S.	2009	RASA1
11	Aberrant GM-CSF signal transduction pathway in juvenile myelomonocytic leukemia assayed by flow cytometric intracellular STAT5 phosphorylation measurement. (18830265)	Gaipa G.... Biondi A.	2009	STAT5A, CSF2
12	Concomitant EBV-related B-cell proliferation and juvenile myelomonocytic leukemia in a 2-year-old child. (17618684)	Janik-Moszant A.... Szczepanski T.	2008	NRAS
13	Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay. (18164384)	Tanaka M.... Kojima S.	2008	CSF2
14	Mutation analysis of SIPA1 in patients with juvenile myelomonocytic leukemia. (18492118)	Yoshida N.... Kojima S.	2008	SIPA1
15	Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. (19047918)	Yoshida N.... Kojima S.	2008	PTPN11, NRAS, KRAS
16	Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. (18000165)	Archambeault S.... Loh M.L.	2008	PTPN11, NRAS, KRAS
17	Juvenile myelomonocytic leukemia with less aggressive clinical course and KRAS mutation. (18561174)	Imamura M.... Uchiyama M.	2008	KRAS
18	Mutation analysis of AML1 gene in pediatric primary myelodysplastic syndrome and juvenile myelomonocytic leukemia. (17935781)	Masunaga A.... Nakahata T.	2008	RUNX1
19	Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia. (18024410)	de Vries A.C.... van den Heuvel-Eibrink M.M.	2007	BRAF
20	Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. (17353900)	Flotho C.... Niemeyer C.M.	2007	PTPN11, NF1
21	Mutation analysis of Son of Sevenless in juvenile myelomonocytic leukemia. (17315019)	Kratz C.P.... Zenker M.	2007	SOS1
22	Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia. (18024405)	de Vries A.C.... van den Heuvel-Eibrink M.M.	2007	FLT3
23	Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia. (17301809)	Buijs A.... Bruin M.	2007	RARA
24	Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. (17332249)	Matsuda K.... Koike K.	2007	NRAS, KRAS
25	Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations. (17268534)	Metzner A.... Jucker M.	2007	PTPN11, KRAS, INPP5D
26	JAK2 V617F mutation is a rare event in juvenile myelomonocytic leukemia. (17151700)	Zecca M.... Niemeyer C.M.	2007	JAK2
27	Respiratory failure, juvenile myelomonocytic leukemia, and neonatal Noonan syndrome. (17414570)	Cheong J.L.... Moorkamp M.H.	2007	PTPN11
28	Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. (16778141)	Hirano N.... Nadler L.M.	2006	HBG1
29	Simultaneous control of third-degree graft-versus-hos t disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMM L) with 6-mercaptopurine following fulminant JMML relapse early after KIR-misma tched bone marrow transplantation. (16344675)	Stachel D.K.... Holter W.	2005	KIR3DL1
30	The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. (15928039)	Kratz C.P.... Loh M.L.	2005	PTPN11
31	Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation. (15857842)	Shimada H.... Takahashi T.	2005	PTPN11
32	JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia. (16079889)	Tono C.... Ito E.	2005	JAK2
33	Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia. (15390271)	Gratias E.J.... Emanuel P.D.	2005	FLT3
34	A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia. (15211660)	Yoshida R.... Ogata T.	2004	PTPN11
35	Juvenile myelomonocytic leukemia. (15087069)	Emanuel P.D.	2004	PTPN11
36	Somatic PTPN11 mutation with a heterogeneous clonal origin in children with juvenile myelomonocytic leukemia. (15085150)	Shimada H.... Kosaki K.	2004	PTPN11
37	Viral infections in juvenile myelomonocytic leukemia: prevalence and clinical implications. (15454834)	Manabe A.... Nakahata T.	2004	MX1
38	HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). (15087372)	Morerio C.... Panarello C.	2004	PDGFRB, SPECC1
39	Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia. (14739366)	Gitler A.D.... Epstein J.A.	2004	NF1, RASA2
40	Expression analysis of alpha-NAC and ANX2 in juvenile myelomonocytic leukemia using SMART polymerase chain reaction and 'virtual Northern' hybridization. (12699894)	Hammerle K.... Flotho C.	2003	ANXA2, NACA
41	Juvenile myelomonocytic leukemia. (12718797)	Niemeyer C.M.... Kratz C.	2003	CSF2
42	Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. (12717436)	Tartaglia M.... Gelb B.D.	2003	PTPN11
43	Juvenile myelomonocytic leukemia. (14521811)	Niemeyer C.M.... Kratz C.	2003	CSF2
44	Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. (12010819)	Iversen P.O.... Sioud M.	2002	RAF1
45	Human herpesvirus 6 infection mimicking juvenile myelomonocytic leukemia in an infant. (11990701)	Lorenzana A.... Emanuel P.D.	2002	CSF2
46	Expression of interferon regulatory factor 1 and 2 in hematopoietic cells of children with juvenile myelomonocytic leukemia. (10609788)	Mild G.C.... Niemeyer C.M.	1999	IRF2, IRF1
47	Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. (9639526)	Side L.E.... Shannon K.M.	1998	NF1
48	EVI-1 gene expression in myeloid clonogenic cells from juvenile myelomonocytic leukemia (JMML). (9447818)	Privitera E.... Biondi A.	1997	RUNX1
49	Interleukin (IL)-10, but not IL-4 or IL-13, inhibits cytokine production and growth in juvenile myelomonocytic leukemia cells. (9012477)	Iversen P.O.... Lopez A.F.	1997	IL13
50	Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. (9389708)	Iversen P.O.... Lopez A.F.	1997	CSF2

Genes related to juvenile myelomonocytic leukemia according to GeneCards:

(show all 42)

id	Symbol	Description	Score	GeneCards Section Context
1	NRAS	neuroblastoma RAS viral (v-ras) oncogene homolog	11.1	Summaries, Publications
2	NF1	neurofibromin 1	11.1	Functions, Publications, Summaries
3	SPECC1	sperm antigen with calponin homology and coiled-coil domains 1	11.1	Summaries, Publications
4	ARHGAP26	Rho GTPase activating protein 26	11.1	Summaries
5	PTPN11	protein tyrosine phosphatase, non-receptor type 11	11.0	Publications
6	KRAS	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog	11.0	Publications
7	CSF2	colony stimulating factor 2 (granulocyte-macrophage)	11.0	Publications
8	RARA	retinoic acid receptor, alpha	11.0	Publications
9	FLT3	fms-related tyrosine kinase 3	11.0	Publications
10	CDKN3	cyclin-dependent kinase inhibitor 3	11.0
11	RUNX1	runt-related transcription factor 1	11.0	Publications
12	PDGFRA	platelet-derived growth factor receptor, alpha polypeptide	11.0
13	SIPA1	signal-induced proliferation-associated 1	11.0	Publications
14	NACA	nascent polypeptide-associated complex alpha subunit	11.0	Publications
15	SAMD9L	sterile alpha motif domain containing 9-like	11.0
16	POLR3G	polymerase (RNA) III (DNA directed) polypeptide G (32kD)	11.0
17	HBG1	hemoglobin, gamma A	11.0	Publications
18	INPP5D	inositol polyphosphate-5-phosphatase, 145kDa	11.0	Publications
19	RASA2	RAS p21 protein activator 2	11.0	Publications
20	KIR3DL1	killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1	11.0	Publications
21	MX1	myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse)	11.0	Publications
22	CBL	Cbl proto-oncogene, E3 ubiquitin protein ligase	11.0	Publications
23	BTD	biotinidase	11.0	Publications
24	TET2	tet methylcytosine dioxygenase 2	11.0	Publications
25	SPRED1	sprouty-related, EVH1 domain containing 1	11.0	Publications
26	IRF1	interferon regulatory factor 1	11.0	Publications
27	IRF2	interferon regulatory factor 2	11.0	Publications
28	RASA1	RAS p21 protein activator (GTPase activating protein) 1	11.0	Publications
29	ANXA2	annexin A2	11.0	Publications
30	STAT5A	signal transducer and activator of transcription 5A	11.0	Publications
31	SOS1	son of sevenless homolog 1 (Drosophila)	11.0	Publications
32	PDGFRB	platelet-derived growth factor receptor, beta polypeptide	11.0	Publications
33	CBLB	Cbl proto-oncogene, E3 ubiquitin protein ligase B	11.0	Publications
34	GAB2	GRB2-associated binding protein 2	11.0
35	HRAS	v-Ha-ras Harvey rat sarcoma viral oncogene homolog	11.0
36	RAF1	v-raf-1 murine leukemia viral oncogene homolog 1	11.0	Publications
37	BRAF	v-raf murine sarcoma viral oncogene homolog B1	11.0	Publications
38	IL13	interleukin 13	11.0	Publications
39	JAK2	Janus kinase 2	11.0	Publications
40	PTEN	phosphatase and tensin homolog	11.0	Publications
41	PTPN3	protein tyrosine phosphatase, non-receptor type 3	11.0
42	TP53	tumor protein p53	11.0	Publications

Pathways related to juvenile myelomonocytic leukemia according to GeneDecks:

(show top 50)    (show all 241)

id	Pathway	Score	Top Affiliating Genes
1	ErbB2-ErbB3 Heterodimers36	10.2	SOS1, RAF1
2	Development_EGFR signaling via small GTPases41	9.9	RAF1, HRAS, CBL
3	Development_EPO-induced Jak-STAT pathway41	9.7	STAT5A, CBL, JAK2, RASA1
4	Adipocytokines & Insulin Signaling37	9.4	BRAF, CBL, SOS1, PTPN11, KRAS
5	Sorafenib Pharmacodynamics34	9.2	BRAF, KRAS, FLT3, HRAS, PDGFRB, RAF1
6	Development EGFR signaling via small GTPases10	9.2	RAF1, RASA1, KRAS, NRAS, HRAS, CBL
7	G-protein signaling_M-RAS regulation pathway41	9.2	RAF1, NF1, SOS1, RASA2, BRAF, RASA1
8	G-protein signaling M-RAS regulation pathway10	9.2	RASA2, BRAF, RAF1, RASA1, NF1, SOS1
9	Pathway_PA16595942534	9.2	NRAS, PDGFRB, KRAS, HRAS, FLT3, RAF1
10	Development_Flt3 signaling41	9.2	PTPN11, FLT3, STAT5A, SOS1, GAB2, HRAS
11	Pathway_PA16598005034	9.1	BRAF, PDGFRA, KRAS, PDGFRB, NRAS, HRAS
12	Non-small cell lung cancer20	9.1	SOS1, KRAS, HRAS, RAF1, BRAF, NRAS
13	Natural killer cell mediated cytotoxicity20	8.8	KRAS, SOS1, CSF2, NRAS, PTPN11, HRAS
14	Development EPO-induced MAPK pathway10	8.8	JAK2, INPP5D, CBL, HRAS, NRAS, SOS1
15	Development_EPO-induced MAPK pathway41	8.8	INPP5D, RAF1, CBL, HRAS, NRAS, KRAS
16	Development Flt3 signaling10	8.8	INPP5D, CBL, PTPN11, STAT5A, SOS1, RAF1
17	Immune response_IL-3 activation and signaling pathway41	8.8	INPP5D, STAT5A, HRAS, SOS1, PTPN11, RAF1
18	Immune response IL-3 activation and signaling pathway10	8.8	PTPN11, INPP5D, HRAS, RAF1, SOS1, STAT5A
19	FLT3 Signaling36	8.8	BRAF, GAB2, STAT5A, NRAS, HRAS, CBL
20	Thrombopoietin Pathway36	8.8	RAF1, JAK2, HRAS, NRAS, STAT5A, SOS1
21	Acute myeloid leukemia20	8.7	BRAF, RARA, RAF1, FLT3, HRAS, NRAS
22	T cell receptor signaling pathway20	8.7	CSF2, SOS1, KRAS, NRAS, HRAS, CBLB
23	Fc epsilon RI signaling pathway20	8.7	NRAS, KRAS, GAB2, HRAS, INPP5D, RAF1
24	Chemotaxis CXCR4 signaling pathway10	8.7	RAF1, RASA1, JAK2, CBL, HRAS, SOS1
25	Chemotaxis_CXCR4 signaling pathway41	8.6	SOS1, PTPN11, HRAS, CBL, JAK2, RASA1
26	Development EPO-induced Jak-STAT pathway10	8.6	PTPN11, RAF1, RASA1, JAK2, STAT5A, SOS1
27	OSM Pathway36	8.6	BRAF, RAF1, HRAS, JAK2, NRAS, SOS1
28	Development Prolactin receptor signaling10	8.6	JAK2, IRF1, HRAS, PTPN11, SOS1, RAF1
29	Development_Prolactin receptor signaling41	8.6	PTPN11, SOS1, RAF1, JAK2, IRF1, CBL
30	Insulin signaling pathway20	8.6	BRAF, KRAS, SOS1, RAF1, INPP5D, CBL
31	ErbB signaling pathway20	8.6	HRAS, NRAS, CBLB, KRAS, STAT5A, SOS1
32	IL-3 Pathway36	8.5	BRAF, STAT5A, JAK2, HRAS, NRAS, SOS1
33	Development_Neurotrophin family signaling41	8.4	SOS1, PTPN11, HRAS, RAF1, BRAF, TP53
34	Development Neurotrophin family signaling10	8.4	PTPN11, SOS1, GAB2, TP53, BRAF, RAF1
35	EGF Pathway36	8.4	HRAS, NRAS, SOS1, JAK2, RASA1, RAF1
36	Pathways in cancer20	8.4	FLT3, RARA, CBL, CBLB, TP53, PTEN
37	PDGF Pathway36	8.4	SOS1, STAT5A, PDGFRB, PDGFRA, NRAS, HRAS
38	Jak-STAT signaling pathway20	8.3	JAK2, IL13, CBL, PTPN11, CSF2, SOS1
39	Tyrosine Kinases / Adaptors3	8.3	CBLB, PDGFRB, GAB2, CBL, ANXA2, FLT3
40	IL-4 Pathway36	8.3	BRAF, RAF1, NRAS, HBG1, SOS1, PTEN
41	Endometrial cancer20	8.1	HRAS, NRAS, SOS1, PTEN, KRAS, TP53
42	Melanoma20	8.0	TP53, PDGFRA, PTEN, HRAS, RAF1, BRAF
43	Endothelin-1 Signaling Pathway36	8.0	CSF2, PDGFRB, PDGFRA, NRAS, HRAS, BRAF
44	Prolactin Signaling36	7.9	SOS1, RAF1, JAK2, HRAS, NRAS, BRAF
45	MAPK signaling pathway20	7.9	BRAF, PDGFRB, PDGFRA, RASA2, NF1, KRAS
46	Glioma20	7.8	SOS1, KRAS, RAF1, HRAS, TP53, PTEN
47	Glioblastoma Multiforme36	7.8	SOS1, PDGFRB, PTEN, TP53, HRAS, RAF1
48	Prostate cancer20	7.8	BRAF, PDGFRA, RAF1, HRAS, TP53, SOS1
49	Chronic myeloid leukemia20	7.5	BRAF, RAF1, CBL, CBLB, HRAS, TP53
50	Molecular Mechanisms of Cancer36	7.3	PTEN, CBL, HRAS, TP53, NRAS, PDGFRA

Compounds related to juvenile myelomonocytic leukemia according to GeneDecks:

(show top 50)    (show all 110)

id	Compound	Score	Top Affiliating Genes
1	threonine32	10.4	RAF1, FLT3
2	inositol32	10.2	INPP5D, RASA2, PTPN11, KIR3DL1, CSF2
3	pkc 41232	9.6	FLT3, PDGFRA, STAT5A, PDGFRB
4	phenylalanine32	9.5	JAK2, CBL, RASA1, INPP5D, BTD, RASA2
5	ifn-alpha32	9.4	STAT5A, MX1, IRF1, IL13, CSF2, PTPN11
6	guanosine32 9 18 9	12.3	PDGFRB, NF1, IRF1, RASA1, MX1, HRAS
7	sb 20358032 42	10.3	BRAF, IRF1, IL13, PTPN11, STAT5A
8	ly29400232	9.3	IL13, HRAS, PTPN11, KRAS, STAT5A, INPP5D
9	agar32	9.1	HRAS, BRAF, RARA, JAK2, PDGFRB, NRAS
10	cetuximab32 34 9 9	12.1	CDKN3, PTEN, PDGFRB, KRAS, BRAF
11	etoposide32 42 9 9	11.9	RARA, IRF1, FLT3, TP53, PTPN11, RUNX1
12	arginine32	8.9	ANXA2, BRAF, PTPN11, RASA1, BTD, IL13
13	sodium orthovanadate32	8.6	STAT5A, PTPN3, CDKN3, JAK2, RAF1, PTPN11
14	aspartate32	8.5	STAT5A, RARA, RAF1, HRAS, PTPN3, BRAF
15	estrogen32	8.5	ANXA2, PDGFRB, PDGFRA, RARA, HRAS, PTPN3
16	vanadate32	8.5	JAK2, CDKN3, PTPN3, PTPN11, PDGFRB, STAT5A
17	crcs32	8.5	BRAF, HRAS, TP53, PTEN, KRAS
18	arsenite32 18	9.4	FLT3, JAK2, ANXA2, TP53, PTEN, RUNX1
19	rapamycin32 42	9.4	JAK2, RAF1, BRAF, STAT5A, KRAS, HRAS
20	gtp32	8.4	RASA2, KRAS, BRAF, SOS1, NF1, HRAS
21	h2o232	8.3	PDGFRB, PTPN11, CBL, IL13, PTPN3, CDKN3
22	gp 13032	8.1	CSF2, IL13, FLT3, HRAS, JAK2, PTPN11
23	herbimycin a32 42	9.1	PTPN3, HRAS, CDKN3, JAK2, RAF1, FLT3
24	lactacystin32	8.0	CBL, CDKN3, JAK2, RAF1, TP53, PTPN3
25	doxorubicin32 34 9 9	10.9	HRAS, PTEN, HBG1, TP53, CSF2, RUNX1
26	paraffin32	7.6	RARA, KRAS, PDGFRB, NF1, PTEN, TP53
27	leucine32	7.5	CBLB, PDGFRB, STAT5A, HRAS, KIR3DL1, CBL
28	vegf32	7.5	PDGFRB, KRAS, CSF2, RUNX1, PDGFRA, BRAF
29	cysteine32	7.5	BTD, RARA, PTEN, PTPN3, PDGFRB, CSF2
30	butyrate32	7.5	IRF1, RUNX1, RARA, RAF1, JAK2, CDKN3
31	thymidine32 18	8.5	PDGFRA, PTPN11, STAT5A, IRF1, RAF1, RARA
32	cisplatin32 34 9 9	10.3	BRAF, RAF1, JAK2, CDKN3, HRAS, PTEN
33	imatinib32 34 9 9	10.3	BRAF, RARA, JAK2, FLT3, CBL, PTEN
34	genistein32 9 18 9	10.0	CDKN3, HRAS, PTEN, JAK2, PTPN3, PDGFRB
35	paclitaxel32 34 9 9	10.0	BRAF, RARA, RAF1, ANXA2, PTPN3, PTEN
36	pd 98,05932	6.8	BRAF, JAK2, IL13, HRAS, PTEN, PTPN3
37	nitric oxide32 9 18 9	9.6	HBG1, JAK2, PTEN, HRAS, IL13, PTPN11
38	atp32	6.4	PTPN3, KIR3DL1, BRAF, HRAS, FLT3, CDKN3
39	cycloheximide32	6.3	RAF1, JAK2, CDKN3, IRF1, IRF2, IL13
40	phosphotyrosine32	6.3	PTPN11, PDGFRA, PDGFRB, STAT5A, PTEN, CBL
41	phosphoinositide32	6.1	GAB2, KRAS, PDGFRB, BRAF, RARA, PTPN11
42	wortmannin32 42	7.1	BRAF, RAF1, JAK2, CDKN3, INPP5D, IL13
43	oligonucleotide32	5.9	RUNX1, STAT5A, KRAS, PDGFRB, PDGFRA, NF1
44	alanine32	5.7	PTPN11, BTD, BRAF, RARA, RASA1, MX1
45	calcium32 9 18 9	8.4	HRAS, PTEN, PTPN3, PDGFRB, PTPN11, PDGFRA
46	retinoic acid32 42 18	7.4	TP53, HRAS, CBL, ANXA2, IL13, FLT3
47	lipid32	5.0	PDGFRB, INPP5D, CBL, ANXA2, IRF1, JAK2
48	phosphatidylinositol32	3.9	CSF2, INPP5D, FLT3, IRF1, CDKN3, JAK2
49	serine32	3.5	STAT5A, RUNX1, GAB2, SOS1, KRAS, JAK2
50	tyrosine32	3.1	GAB2, RUNX1, CSF2, SOS1, STAT5A, KRAS

Cellular components related to juvenile myelomonocytic leukemia according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	intrinsic to plasma membrane	GO:031226	10.1	PDGFRA, PDGFRB
2	cytosol	GO:005829	4.9	BRAF, TP53, PTEN, PTPN11, HBG1, STAT5A
3	nucleus	GO:005634	4.7	PTEN, SPRED1, SPECC1, NF1, PDGFRA, PDGFRB
4	cytoplasm	GO:005737	3.6	TP53, PTEN, PTPN3, PTPN11, SPRED1, NF1

Biological processes related to juvenile myelomonocytic leukemia according to GeneDecks:

(show all 37)

id	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of Rac protein signal transduction	GO:035022	10.3	HRAS, NRAS, KRAS
2	striated muscle cell differentiation	GO:051146	10.2	HRAS, NRAS, KRAS
3	regulation of synaptic transmission, GABAergic	GO:032228	10.2	KRAS, NF1, NRAS, HRAS
4	regulation of long-term neuronal synaptic plasticity	GO:048169	10.2	KRAS, NF1, NRAS, HRAS
5	visual learning	GO:008542	10.2	HRAS, NRAS, NF1, KRAS
6	positive regulation of phosphatidylinositol 3-kinase activity	GO:043552	10.1	PDGFRB, PDGFRA, FLT3
7	metanephric glomerular capillary formation	GO:072277	10.1	PDGFRB, PDGFRA
8	type I interferon-mediated signaling pathway	GO:060337	10.0	PTPN11, IRF2, IRF1, MX1
9	actin cytoskeleton organization	GO:030036	10.0	KRAS, NF1, NRAS, HRAS, ARHGAP26
10	positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	GO:038091	10.0	PDGFRB, PDGFRA
11	activation of MAPKK activity	GO:000186	9.9	RAF1, JAK2, NRAS
12	MAPK cascade	GO:000165	9.8	KRAS, NF1, NRAS, HRAS, RAF1
13	leukocyte migration	GO:050900	9.8	SOS1, KRAS, NRAS, PTPN11, HRAS, INPP5D
14	platelet-derived growth factor receptor signaling pathway	GO:048008	9.7	PDGFRB, PDGFRA, JAK2
15	interferon-gamma-mediated signaling pathway	GO:060333	9.7	PTPN11, IRF2, IRF1, JAK2
16	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	9.6	PDGFRB, PDGFRA, CBL, FLT3, JAK2
17	negative regulation of neuron apoptotic process	GO:043524	9.6	KRAS, NRAS, HRAS, RASA1, BRAF
18	peptidyl-tyrosine phosphorylation	GO:018108	9.5	STAT5A, PDGFRB, PDGFRA, FLT3, JAK2
19	insulin receptor signaling pathway	GO:008286	9.5	SOS1, KRAS, NRAS, PTPN11, HRAS, RAF1
20	positive regulation of ERK1 and ERK2 cascade	GO:070374	9.4	BRAF, HRAS, PDGFRA, PDGFRB
21	social behavior	GO:035176	9.4	HRAS, PTEN, KRAS
22	phosphatidylinositol-mediated signaling	GO:048015	9.3	PTEN, PDGFRA, PDGFRB, GAB2
23	axon guidance	GO:007411	9.3	SOS1, KRAS, NRAS, PTPN11, HRAS, RAF1
24	intracellular signal transduction	GO:035556	9.2	SIPA1, CBLB, INPP5D, JAK2, RASA1, RASA2
25	cytokine-mediated signaling pathway	GO:019221	9.2	STAT5A, MX1, JAK2, IRF1, IRF2, FLT3
26	peptidyl-tyrosine dephosphorylation	GO:035335	9.1	PTPN11, PTPN3, PTEN, CDKN3
27	small GTPase mediated signal transduction	GO:007264	9.1	SOS1, KRAS, NRAS, HRAS, ARHGAP26, RAF1
28	Ras protein signal transduction	GO:007265	9.1	SOS1, KRAS, NF1, NRAS, TP53, HRAS
29	epidermal growth factor receptor signaling pathway	GO:007173	8.8	SOS1, KRAS, NRAS, PTPN11, PTEN, HRAS
30	nerve growth factor receptor signaling pathway	GO:048011	8.5	RAF1, HRAS, PTEN, PTPN11, NRAS, KRAS
31	negative regulation of apoptotic process	GO:043066	8.5	CSF2, PTEN, TP53, CBL, RAF1, BRAF
32	fibroblast growth factor receptor signaling pathway	GO:008543	8.4	BRAF, SOS1, KRAS, NRAS, PTPN11, PTEN
33	positive regulation of cell proliferation	GO:008284	8.1	GAB2, CSF2, KRAS, PDGFRB, PDGFRA, NRAS
34	negative regulation of cell proliferation	GO:008285	8.0	PTEN, TP53, HRAS, FLT3, IRF1, CDKN3
35	cell proliferation	GO:008283	8.0	SIPA1, PTEN, TP53, HRAS, IRF2, RAF1
36	blood coagulation	GO:007596	7.8	PTPN11, NRAS, KRAS, HBG1, SOS1, TP53
37	signal transduction	GO:007165	7.3	SIPA1, SOS1, PDGFRB, HRAS, CBLB, IL13

Molecular functions related to juvenile myelomonocytic leukemia according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	vascular endothelial growth factor-activated receptor activity	GO:005021	10.0	FLT3, PDGFRA, PDGFRB
2	regulatory region DNA binding	GO:000975	9.9	RUNX1, IRF2, IRF1
3	vascular endothelial growth factor binding	GO:038085	9.8	PDGFRB, PDGFRA
4	phosphotyrosine binding	GO:001784	9.1	CBL, CBLB, PTPN3
5	protein tyrosine phosphatase activity	GO:004725	8.8	CDKN3, PTEN, PTPN3, PTPN11
6	protein binding	GO:005515	2.2	GAB2, TP53, PTEN, PTPN3, PTPN11, SPRED1